Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

Completed · Phase 4 · Has a placebo group

Conditions studied: HIV Infections, Fatigue

In brief

This study will determine whether armodafinil (Nuvigil), an FDA approved medication, is effective in reducing fatigue in adults with HIV/AIDS.

Key facts

Study ID

NCT00737204

Run by

New York State Psychiatric Institute

People needed

70

Starts

2008-06-01

Expected to finish

2010-09-01

Last updated by the study team

2014-06-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 18-75
• HIV+
• Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus impairment on 1+ categories of Role Function Scale)
• Fatigue duration for 3+ months
• English-speaking
• Able to give informed consent
• Fecund women uses barrier method of contraception

You may not qualify if…

• Primary care doctor does not approve of study participation
• Unstable medical condition (e.g. liver failure; cirrhosis, new onset opportunistic infection in past month)
• Untreated hypogonadism, except for men for whom testosterone replacement is medically contraindicated (serum testosterone below the reference range)
• Untreated hypothyroidism (Thyroid Stimulating Hormone over 5 IUI/mL)
• Untreated and uncontrolled hypertension
• Clinically significant anemia (hematocrit <30%)
• Started testosterone or nandrolone in past 6 weeks
• Started or changed an antiretroviral regimen in past 4 weeks if fatigue predated the change; otherwise, started or changed regimen in past 2 months
• Untreated or under-treated major depressive disorder
• Started antidepressant medication within past 6 weeks
• Substance abuse/dependence (past 4 months)
• Regular and frequent cannabis use (> twice/week regularly)
• Currently clinically significant suicidal ideation or Hamilton Depression Scale (HAM-D) score >24
• History or current psychosis or bipolar disorder
• Pregnant or breastfeeding
• Significant untreated insomnia (score >3 on HAM-D insomnia items)
• Currently taking psychostimulant medication or past nonresponse to modafinil
• Has no alternative viable antiretroviral regimen after the current one
• Left ventricular hypertrophy; mitral valve prolapse

Where it is running

• New York State Psychiatric Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.